ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2421

Trends in Glucocorticoid Use in Systemic Lupus Erythematosus in a Population-Based Inception Cohort from 1976 to 2018: The Lupus Midwest Network
Abstract Number: 0509

Trends in Initiation of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially-Insured US Adults, 2001-2021
Abstract Number: 0280

Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform
Abstract Number: 0397

Trends in New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001-2022
Abstract Number: 1877

Trends in Rheumatoid Arthritis Incidence, Prevalence, DALY and Death Rates (1991-2021) in the United States: A Comprehensive Analysis of State-Level Disparities
Abstract Number: 0625

Trends, Outcomes, and Predictors of Mortality in Patients with SLE Hospitalized for Influenza
Abstract Number: 2167

Trust and Shared Decision-Making in Adolescents with Systemic Lupus Erythematosus: Findings from a Pilot Survey Design Study
Abstract Number: 0650

Tubulointerstitial Inflammation Predicts Tubular Atrophy, Fibrosis, and Renal Function Loss in Lupus Nephritis
Abstract Number: 1349

Two Composite Cytokine Scores Predict Flare and Drug-free Remission in Patients with Rheumatoid Arthritis
Abstract Number: 2168

Two Year Data on Quality of Life, Pain and Mobility Scores After Rituximab Treatment in the Preclinical Phase of Rheumatoid Arthritis
Abstract Number: 0381

Two- and 3-Year Outcomes of the Childhood Arthritis and Rheumatology Research Alliance FROST Study of New-onset Systemic JIA Treatment
Abstract Number: 2612

Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients Vaccinated with Recombinant Herpes Zoster Vaccine: An Interim Analysis of a Prospective Randomized Phase 4 Study
Abstract Number: 0862

Two-year’s Worsening of Semi-quantitative MRI Features as Surrogate Outcomes for Long-term Incident Radiographic Knee Osteoarthritis After ACL-rupture
Abstract Number: 0001

Type I Interferon and Anifrolumab Effects on Bone Marrow and Blood Plasma Cells in Systemic Lupus Erythematosus
Abstract Number: 2303

Type I Interferon Signature Drives Phenotypic Clusters of Sjögren’s Disease and Can Predict Systemic Evolution Among the “B-cell Active with Low Symptoms” Subgroup

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].